Assessing Surveillance Utilization and Value in Commercially Insured Patients With Colorectal Cancer
Trends in surveillance testing after treatment for colorectal cancer remained relatively stable recently, and patients who overutilized surveillance measures had quicker recurrence detection but ...
NEW YORK (Reuters Health) - The results of new research indicate that many older patients who survive colorectal cancer do not attend the guideline-recommended follow-up office visits or undergo ...
A pair of common tests might help colorectal cancer patients who have undergone surgery remain cancer-free, British researchers say. Both a standard CT scan and a blood test known as CEA ...
Blood test for minimal residual disease (MRD) now covered to monitor for disease recurrence after curative intent treatment Tissue-free approach addresses need for cancer patients who have no tissue ...
Retrospective health care claims database analysis of direct medical costs of newly diagnosed patients (pts) with hepatocellular carcinoma (HCC) in the United States. Background: Relapse after ...
A cohort of 250 patients diagnosed with stage II or III CRC in 2004 and alive 42 months after diagnosis was identified from health administrative data in Manitoba, Canada. Colonoscopy, liver imaging, ...
A new secondary analysis of a randomized clinical trial examined 10-year mortality data from 2456 patients diagnosed with stage II or III colorectal cancer. Improved treatments for metastatic disease ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Palmetto GBA, a Medicare administrative contractor that administers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results